BioSpace News Archive

Rubius Therapeutics, Inc. announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and plans to engage an investment bank to act as a strategic advisor for this process.

Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform delivery technology, today reported financial and operational results for the third quarter ended September 30, 2022, along with a corporate update.

Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced that Chinook management is scheduled to participate in the following upcoming investor conferences.

Replimune Group, Inc., a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, announced that members from the Replimune management team will present and host investor meetings at the following two conferences.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter 2022.

INmune Bio, Inc. reported its financial results for the quarter ended September 30, 2022 and provides a business update.

Equillium, Inc. today announced that it has initiated a Phase 1 study of EQ102 in healthy volunteers.

Inogen, Inc. today announced financial results for the quarter ended September 30, 2022, and provided a business update.

OrsoBio, Inc. today announced its acquisition of an ACMSD inhibitor program from Mitobridge, an Astellas Company.

Albireo Pharma, Inc. announced the completion of patient enrollment in the BOLD study, a global gold standard Phase 3 pivotal trial of Bylvay in 205 patients with biliary atresia over 24 months.